PL2655604T3 - Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom - Google Patents
Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusomInfo
- Publication number
- PL2655604T3 PL2655604T3 PL11849865T PL11849865T PL2655604T3 PL 2655604 T3 PL2655604 T3 PL 2655604T3 PL 11849865 T PL11849865 T PL 11849865T PL 11849865 T PL11849865 T PL 11849865T PL 2655604 T3 PL2655604 T3 PL 2655604T3
- Authority
- PL
- Poland
- Prior art keywords
- serotype
- adenovirus
- filovirus vaccines
- filovirus
- vaccines
- Prior art date
Links
- 241000711950 Filoviridae Species 0.000 title 1
- 241000205701 Human adenovirus 26 Species 0.000 title 1
- 241000701124 Human adenovirus 35 Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42295410P | 2010-12-14 | 2010-12-14 | |
| EP11849865.8A EP2655604B1 (en) | 2010-12-14 | 2011-12-14 | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| PCT/US2011/064944 WO2012082918A1 (en) | 2010-12-14 | 2011-12-14 | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2655604T3 true PL2655604T3 (pl) | 2019-02-28 |
Family
ID=46245095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11849865T PL2655604T3 (pl) | 2010-12-14 | 2011-12-14 | Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9701718B2 (enExample) |
| EP (1) | EP2655604B1 (enExample) |
| JP (2) | JP6054876B2 (enExample) |
| KR (1) | KR101879892B1 (enExample) |
| CN (1) | CN103370411B (enExample) |
| AU (1) | AU2011343798B2 (enExample) |
| BR (1) | BR112013014712B1 (enExample) |
| CA (1) | CA2821289C (enExample) |
| DK (1) | DK2655604T3 (enExample) |
| EA (1) | EA029504B1 (enExample) |
| ES (1) | ES2676196T3 (enExample) |
| PL (1) | PL2655604T3 (enExample) |
| WO (1) | WO2012082918A1 (enExample) |
| ZA (1) | ZA201304260B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9701718B2 (en) | 2010-12-14 | 2017-07-11 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| SG11201610446XA (en) | 2014-06-26 | 2017-01-27 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| US10561721B2 (en) | 2014-09-03 | 2020-02-18 | Bavarian Nordic A/S | Methods and compositions for inducing protective immunity against filovirus infection |
| MX2017002890A (es) | 2014-09-03 | 2017-11-13 | Bavarian Nordic As | Métodos y composiciones para potenciar respuestas inmunitarias. |
| CN112121160A (zh) | 2014-09-26 | 2020-12-25 | 贝斯以色列护理医疗中心有限公司 | 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物 |
| US20180052173A1 (en) | 2015-03-18 | 2018-02-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
| TWI707039B (zh) | 2015-12-15 | 2020-10-11 | 荷蘭商傑森疫苗防護公司 | 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法 |
| MX2018009997A (es) | 2016-02-18 | 2019-02-07 | Int Flavors & Fragrances Inc | Composiciones de cápsulas de poliurea. |
| MX2018011341A (es) | 2016-03-18 | 2019-07-04 | Int Flavors & Fragrances Inc | Microcápsulas de sílice y métodos para prepararlas. |
| AU2017286375B2 (en) | 2016-06-16 | 2019-04-18 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
| EP4438132A3 (en) | 2016-07-01 | 2025-01-15 | International Flavors & Fragrances Inc. | Stable microcapsule compositions |
| WO2018011198A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| WO2018011768A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines And Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| MX2019003078A (es) | 2016-09-16 | 2019-07-08 | Int Flavors & Fragrances Inc | Composiciones de microcapsulas estabilizadas con agentes de control de la viscosidad. |
| US20180085291A1 (en) | 2016-09-28 | 2018-03-29 | International Flavors & Fragrances Inc. | Microcapsule compositions containing amino silicone |
| US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
| US20180346648A1 (en) | 2017-05-30 | 2018-12-06 | International Flavors & Fragrances Inc. | Branched polyethyleneimine microcapsules |
| BR112019026126A2 (pt) | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
| CN111163799A (zh) | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
| WO2019099970A1 (en) | 2017-11-20 | 2019-05-23 | Janssen Pharmaceuticals Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
| MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
| EP4667651A2 (en) | 2018-04-27 | 2025-12-24 | International Flavors and Fragrances Inc. | Stable polyurea microcapsule compositions |
| WO2020016394A1 (en) | 2018-07-20 | 2020-01-23 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing zika antigen with improved productivity |
| CN112770770A (zh) | 2018-09-25 | 2021-05-07 | 扬森疫苗与预防公司 | 共定位施用疫苗组分诱导针对人类免疫缺陷病毒的免疫应答的方法 |
| CN120694898A (zh) | 2018-12-18 | 2025-09-26 | 国际香料和香精公司 | 瓜尔胶微胶囊 |
| MX2021013950A (es) | 2019-05-14 | 2022-01-04 | Janssen Biotech Inc | Eliminacion eficaz de impurezas usando un proceso de diafiltracion. |
| US20230075527A1 (en) | 2020-01-31 | 2023-03-09 | Janssen Pharmaceuticals, Inc | Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines |
| IL298055A (en) | 2020-05-11 | 2023-01-01 | Janssen Pharmaceuticals Inc | Stabilized coronavirus spike protein fusion proteins |
| BR112022026408A2 (pt) | 2020-06-29 | 2023-01-17 | Janssen Vaccines & Prevention Bv | Combinação vacinal contra infecção pelo vírus sincicial respiratório |
| JP2023532369A (ja) | 2020-07-06 | 2023-07-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 安定化されたコロナウイルススパイクタンパク質融合タンパク質 |
| EP4178613A1 (en) | 2020-07-08 | 2023-05-17 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
| MX2022002609A (es) * | 2020-08-22 | 2022-06-08 | Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte | Vector de expresion para el desarrollo de un agente inmunobiologico para inducir inmunidad especifica contra el virus de sindrome respiratorio agudo grave sars-cov-2 (variantes). |
| MX2023009738A (es) | 2021-02-19 | 2023-08-30 | Janssen Vaccines & Prevention Bv | Antigenos de rsv fb prefusion estabilizados. |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| CN118234739A (zh) | 2021-04-01 | 2024-06-21 | 扬森疫苗与预防公司 | 稳定的融合前piv3 f蛋白 |
| EP4124383A1 (en) | 2021-07-27 | 2023-02-01 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4154974A1 (en) | 2021-09-23 | 2023-03-29 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| EP4590689A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| EP4598939A1 (en) | 2022-10-06 | 2025-08-13 | MSD International Business GmbH | Stabilized pre-fusion piv3 f proteins |
| EP4406641A1 (en) | 2023-01-26 | 2024-07-31 | International Flavors & Fragrances Inc. | Biodegradable microcapsules containing low log p fragrance |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852324B1 (en) * | 1997-12-23 | 2005-02-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunization for ebola virus infection |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| CA2776522C (en) * | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| JP4495588B2 (ja) | 2002-04-25 | 2010-07-07 | クルセル ホランド ベー ヴェー | 安定なアデノウイルスベクターおよびその増殖方法 |
| PT1497438E (pt) | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Meios e métodos para a produção de vectores de adenovírus |
| WO2004037294A2 (en) * | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| WO2005012538A2 (en) * | 2003-08-01 | 2005-02-10 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Accelerated vaccination |
| US8101739B2 (en) | 2004-09-27 | 2012-01-24 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector |
| ES2358523T3 (es) * | 2004-10-13 | 2011-05-11 | Crucell Holland B.V. | Vectores adenovirales mejorados y usos de los mismos. |
| NZ553889A (en) | 2004-10-13 | 2009-11-27 | Crucell Holland Bv | Replication-defective adenovirus comprising a chimeric hexon protein and replaced hypervariable ragions HVR1-7 |
| EA016648B1 (ru) * | 2004-10-14 | 2012-06-29 | Круселл Холланд Б.В. | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии |
| WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| US20110091496A1 (en) * | 2008-01-19 | 2011-04-21 | Graham Barney S | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| US9701718B2 (en) | 2010-12-14 | 2017-07-11 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
-
2011
- 2011-12-14 US US13/994,532 patent/US9701718B2/en active Active
- 2011-12-14 PL PL11849865T patent/PL2655604T3/pl unknown
- 2011-12-14 BR BR112013014712-1A patent/BR112013014712B1/pt not_active IP Right Cessation
- 2011-12-14 DK DK11849865.8T patent/DK2655604T3/en active
- 2011-12-14 JP JP2013544747A patent/JP6054876B2/ja active Active
- 2011-12-14 ES ES11849865.8T patent/ES2676196T3/es active Active
- 2011-12-14 CN CN201180067429.7A patent/CN103370411B/zh active Active
- 2011-12-14 AU AU2011343798A patent/AU2011343798B2/en not_active Ceased
- 2011-12-14 WO PCT/US2011/064944 patent/WO2012082918A1/en not_active Ceased
- 2011-12-14 EP EP11849865.8A patent/EP2655604B1/en active Active
- 2011-12-14 KR KR1020137016833A patent/KR101879892B1/ko not_active Expired - Fee Related
- 2011-12-14 EA EA201390866A patent/EA029504B1/ru not_active IP Right Cessation
- 2011-12-14 CA CA2821289A patent/CA2821289C/en active Active
-
2013
- 2013-06-10 ZA ZA2013/04260A patent/ZA201304260B/en unknown
-
2016
- 2016-10-21 JP JP2016206679A patent/JP6268258B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9701718B2 (en) | 2017-07-11 |
| AU2011343798A1 (en) | 2013-07-11 |
| KR20140019304A (ko) | 2014-02-14 |
| US20140017278A1 (en) | 2014-01-16 |
| CN103370411A (zh) | 2013-10-23 |
| CN103370411B (zh) | 2016-05-04 |
| KR101879892B1 (ko) | 2018-08-17 |
| EP2655604A4 (en) | 2015-01-28 |
| CA2821289A1 (en) | 2012-06-21 |
| BR112013014712A2 (pt) | 2017-06-06 |
| JP6054876B2 (ja) | 2016-12-27 |
| EP2655604A1 (en) | 2013-10-30 |
| JP6268258B2 (ja) | 2018-01-24 |
| AU2011343798B2 (en) | 2016-07-14 |
| EA201390866A1 (ru) | 2014-05-30 |
| ZA201304260B (en) | 2021-05-26 |
| ES2676196T3 (es) | 2018-07-17 |
| JP2017048207A (ja) | 2017-03-09 |
| BR112013014712B1 (pt) | 2021-03-02 |
| WO2012082918A1 (en) | 2012-06-21 |
| DK2655604T3 (en) | 2018-08-06 |
| EA029504B1 (ru) | 2018-04-30 |
| JP2014503206A (ja) | 2014-02-13 |
| CA2821289C (en) | 2019-05-21 |
| EP2655604B1 (en) | 2018-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201304260B (en) | Adenovirus serotype 26 and serotype 35 filovirus vaccines | |
| IL249669A0 (en) | Converted 5-fluoro-1h-pyrazolopyridines and their use | |
| EP2560680A4 (en) | FILOVIRUS VACCINES ON CHIMPANZEE ADENOVINE VECTOR BASE | |
| PT2652025T (pt) | Composição secante e a sua utilização | |
| MY158037A (en) | Amphiphilic polysiloxane prepolymers and uses thereof | |
| IL215389A0 (en) | Pneumococcal vaccine and uses thereof | |
| SMT201700357T1 (it) | Ariltriazoloni legati attraverso bis-arile e loro impiego | |
| SI2605757T1 (sl) | Formulacije na osnovi nalbufina in njihove uporabe | |
| ZA201300930B (en) | St-246 liquid formulations and methods | |
| SG173751A1 (en) | Foxm1 peptides and vaccines containing the same | |
| HUE041512T2 (hu) | Új kombináció és alkalmazás | |
| ZA201209237B (en) | Furanyl compounds and the use thereof | |
| AP2013006972A0 (en) | Adenovirus serotype 26 and serotype 35 filovirus vaccines | |
| ZA201303886B (en) | Tomm34 peptides and vaccines including the same | |
| IL214453A0 (en) | Vangli peptides and vaccines including the same | |
| IL221474A0 (en) | Hjurp peptides and vaccines including the same | |
| ZA201207342B (en) | Ect2 peptides and vaccines including the same | |
| IL220146A0 (en) | Tmem22 peptides and vaccines including the same | |
| IL215268A0 (en) | C6orf167 peptides and vaccines containing the same | |
| IL225553A0 (en) | 54orf18c peptides and vaccines containing them | |
| IL225552A0 (en) | wdhd1 peptides and vaccines containing them | |
| EP2657236A4 (en) | NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE |